TABLE 2.
Clinical trials of berberine against cancers.
| Compound | Cancer type | Status | Phase | Treatment | Participants | Control | Combination | References |
|---|---|---|---|---|---|---|---|---|
| Berberine hydrochloride | Colorectal Adenomas | 2017-present | II, III | 300 mg tablet by mouth, 2 times/day for 3 years | 1,000 | Placebo | — | ClinicalTrials.gov Chen et al. (2020c) |
| 2014–2018 Completed | 300 mg, 2 times/day for 2–3 years | 1,108 | — | |||||
| 2017-present | 100 or 300 mg tablet by mouth, 2 times/day for 6 months | 100 | — | |||||
| Berberine Sulfate | Advanced Non-small Cell Lung Cancer (EGFR Mutation) | 2018-present | II | 50 mg, p.o., 3 times/day (tid) | 50 | — | Gefitinib (250 mg p.o., daily) | |
| Berberine | Non-small Cell Lung Cancer | 2004–2006 Completed | — | 20 mg/kg, once a day for 6 weeks | 90 | Placebo | Radiation therapy (Once a day, 2-Gy to total 60–70 Gy) | Liu et al. (2008b) |
| Seminoma | 2002–2008 Completed | 300 mg tablet, p.o., 3 times/day for 5 weeks | 7 | Radiation therapy (1.8-Gy/fraction to total 36 Gy) | Li et al. (2010) | |||
| Lymphomas | 29 | |||||||
| Cervical Cancer | 42 | Radiation therapy (2-Gy/fraction to total 46 Gy) |
Note: per os (p.o.), third in die (tid), Gray (Gy), and epidermal growth factor receptor (EGFR).